Alzheon Inc. believes the reworked active ingredient of its in-licensed compound ALZ-801 can prove a success in treating a subset of Alzheimer's disease patients, and plans a NASDAQ listing to raise the funds for a Phase III clinical trial set to start later this year.
But the preliminary funing target of $80m may not be enough to get the drug approved if FDA isn't content with just one pivotal